Table 3.

Secondary efficacy endpoint data (Propensity Score–Matched Efficacy Set).

Endpoint	Regdanvimab (n = 113)	Control (n = 161)	P value*
Patients with severe symptoms or death due to SARS-CoV-2 infection up to Day 10, n (%)	7 (6.2)	21 (13.0)	0.0654
Patients requiring mechanical ventilation up to Day 28, n (%)	0	1 (0.6)	1.0000†
Duration of mechanical ventilation, days, mean (SD)	0	22.79 (NC)	NC
Patients requiring supplemental oxygen therapy up to Day 28, n (%)	9 (8.0)	30 (18.6)	0.0128
Duration of supplemental oxygen therapy, days, mean (SD)	4.7 (7.1)	8.6 (6.1)	0.1070
Duration of hospitalization up to Day 28‡, days, mean (SD)	12.4 (3.7)	14.6 (5.6)	<0.0001
Patients requiring corticosteroid therapy up to Day 28, n (%)	0	20 (12.4)	<0.0001
Patients requiring remdesivir therapy up to Day 28, n (%)	1 (0.9)	23 (14.3)	0.0001
Duration of fever, days, mean (SD)	2.3 (1.1)	2.5 (1.7)	0.5252
Patients dying of any cause, n (%)	0	2 (1.2)	0.5136†

NC, not calculated; SD, standard deviation.

^*P-value is derived from Student t-test for continuous variables and chi-squared test for categorical variables.

^†P-value derived from Fisher’s exact test, since chi-squared test may not be valid due to 50% of the cells having expected counts<5.

^‡Two patients in the control group who died were not included for the purpose of this endpoint (regdanvimab = 113; control = 153). Duration of hospitalization for patients hospitalized over Day 28 was calculated as being hospitalized for 28 days. Patients transferred to other hospitals were included in this analysis, with duration calculated as the duration of admission at the study site.